Navigation Links
Use of MarginProbe® in DCIS Patients Presented at San Antonio Breast Cancer Symposium
Date:12/8/2011

FRAMINGHAM, Mass., Dec. 8, 2011 /PRNewswire/ -- An analysis of the MarginProbe pivotal study for patients with ductal carcinoma in situ (DCIS) and invasive lobular carcinoma (ILC) were presented today during the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.  The results were presented by Dr. Susan K. Boolbol, Chief, Division of Breast Surgery, Beth Israel Medical Center, New York, New York.  In patients with DCIS or ILC, adjunctive use of MarginProbe significantly improved surgical outcomes by increasing surgeons' ability to identify and immediately resect positive margins, reducing the number of patients requiring re-excision by 49% and 64% respectively.

"DCIS and ILC represent a particular challenge to the breast surgeon," said Dr. Boolbol.  "Current intraoperative techniques are sub-optimal, leading to re-excision rates as high as 40%, as reported in the literature.  These study results represent a tremendous opportunity for breast surgeons to improve the quality of care they offer their patients."

"These results further reinforce the evidence of MarginProbe's benefit in all disease types, including the most challenging DCIS and lobular cases.  These results mirror those seen in Germany in our post-market study," said Dan Levangie, CEO of Dune Medical Devices.  "Across multiple studies, in the U.S., Europe, and Israel, adjunctive use of MarginProbe has consistently led to a 50% reduction in the number of patients requiring re-excision surgery in all disease types."

About the MarginProbe System

The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer.  The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.  The MarginProbe System is Dune's first commercial product and is commercially available in Europe.  The MarginProbe device is an investigational device in the U.S.

About Dune Medical Devices

Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology.  Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. 

Dune Medical Devices is a privately held company financed by Apax Partners since 2004.  It has offices in the U.S., Israel, Germany and Switzerland.  For more information, please visit www.dunemedical.com   

Contact:
Michael Graffeo
Dune Medical Devices
Michael.graffeo@dunemedical.com 
(508) 620-2782


'/>"/>
SOURCE Dune Medical Devices
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MarginProbe® Pivotal Study Presented at San Antonio Breast Cancer Symposium
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. Many Heart Attack Patients Dont Get Best Emergency Treatment
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global fluoropolymer market in the healthcare industry ... Global Fluoropolymer Market in the Healthcare Industry 2016-2020, ... from industry experts. The report covers the market landscape and its ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
(Date:1/17/2017)... -- Research and Markets has announced the addition of ... (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), ... report to their offering. ... The global active pharmaceutical ingredients market is expected to ... 2016, growing at a CAGR of 6.3% from 2016 to 2021. ...
Breaking Medicine Technology:
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Healthful-Flex. , The company, owned and operated by Ed Stroup, was created ... reasonable price with the highest level of customer service. Healthful Balance products can ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... ... January 17, 2017 , ... Metro Development Group has ... high speed technology into the fabric of an entire community. A highlight of ... and wellness in a yet-to-be-named, health focused campus. Leading this initiative in partnership ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Mirror Mirror ... earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, ... part of this elite group of providers. , Produced by Zeltiq, CoolSculpting is ...
Breaking Medicine News(10 mins):